StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) stock

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$29.54−1.08 (-3.53%)

Close on Nov 13, 2026Market cap $1.16BP/E –Yield –

Alto Neuroscience cash

Cash and short-term investments held at the end of each period.

Alto Neuroscience's cash was $319.34M at Sep 30, 2026. For fiscal 2025 it was $176.48M, up 4.6% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$176.48M+4.6%
FY2024Dec 31, 2024$168.73M+104.4%
FY2023Dec 31, 2023$82.55M+70.8%
FY2022Dec 31, 2022$48.34M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$319.34M+130.9%
Q2 FY2026Jun 30, 2026$243.73M+64.6%
Q1 FY2026Mar 31, 2026$263.76M+63.6%
Q4 FY2025Dec 31, 2025$176.48M+4.6%
Q3 FY2025Sep 30, 2025$138.32M-24.1%
Q2 FY2025Jun 30, 2025$148.09M-23.5%
Q1 FY2025Mar 31, 2025$161.25M-21.7%
Q4 FY2024Dec 31, 2024$168.73M+104.4%
Q3 FY2024Sep 30, 2024$182.20M+255.3%
Q2 FY2024Jun 30, 2024$193.62M+228.0%
Q1 FY2024Mar 31, 2024$205.90M+213.0%
Q4 FY2023Dec 31, 2023$82.55M+70.8%
Q3 FY2023Sep 30, 2023$51.29M–
Q2 FY2023Jun 30, 2023$59.03M–
Q1 FY2023Mar 31, 2023$65.78M–
Q4 FY2022Dec 31, 2022$48.34M–

More Alto Neuroscience figures

See a number that looks wrong?